Literature DB >> 1663685

TGF-beta-like activity produced during regression of exacerbations in multiple sclerosis.

J Beck1, P Rondot, P Jullien, J Wietzerbin, D A Lawrence.   

Abstract

Samples representative of different stages of disease from a longitudinal study of multiple sclerosis patients were tested in the anchorage-independent growth assay for TGF-beta and an increased activity was detected in the supernatants from 2-day blood cell cultures from patients with active disease compared to patients without active disease and healthy donors. Within the group of patients with active disease, the TGF-beta like activity was significantly increased in the subgroup of patients tested during the period of regression of the symptoms where it appeared in 86.9% of the samples. These results suggest that TGF-beta or a TGF-beta like factor may play a role in regeneration processes in multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1663685     DOI: 10.1111/j.1600-0404.1991.tb04988.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  10 in total

Review 1.  Cytokine-induced inflammation in the central nervous system revisited.

Authors:  J A Martiney; C Cuff; M Litwak; J Berman; C F Brosnan
Journal:  Neurochem Res       Date:  1998-03       Impact factor: 3.996

Review 2.  Mechanisms of action of interferon-beta in multiple sclerosis.

Authors:  B G Arnason; A Dayal; Z X Qu; M A Jensen; K Genç; A T Reder
Journal:  Springer Semin Immunopathol       Date:  1996

Review 3.  Multiple sclerosis: a unique immunopathological syndrome of the central nervous system.

Authors:  S F Hunter; M Rodriguez
Journal:  Springer Semin Immunopathol       Date:  1995

4.  Low serum interleukin-10 levels in multiple sclerosis: further evidence for decreased systemic immunosuppression?

Authors:  A Salmaggi; A Dufour; M Eoli; E Corsini; L La Mantia; G Massa; A Nespolo; C Milanese
Journal:  J Neurol       Date:  1996-01       Impact factor: 4.849

5.  Elevation of bioactive transforming growth factor-beta in serum from patients with chronic fatigue syndrome.

Authors:  A L Bennett; C C Chao; S Hu; D Buchwald; L R Fagioli; P H Schur; P K Peterson; A L Komaroff
Journal:  J Clin Immunol       Date:  1997-03       Impact factor: 8.317

6.  The protective effects of omega-6 fatty acids in experimental autoimmune encephalomyelitis (EAE) in relation to transforming growth factor-beta 1 (TGF-beta1) up-regulation and increased prostaglandin E2 (PGE2) production.

Authors:  L S Harbige; L Layward; M M Morris-Downes; D C Dumonde; S Amor
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

7.  Blood levels of transforming growth factor-beta 1 (TGF-beta1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN-beta1b).

Authors:  F Nicoletti; R Di Marco; F Patti; E Reggio; A Nicoletti; P Zaccone; F Stivala; P L Meroni; A Reggio
Journal:  Clin Exp Immunol       Date:  1998-07       Impact factor: 4.330

Review 8.  Multiple sclerosis therapy. A practical guide.

Authors:  B W van Oosten; L Truyen; F Barkhof; C H Polman
Journal:  Drugs       Date:  1995-02       Impact factor: 9.546

9.  MicroRNA-142 regulates inflammation and T cell differentiation in an animal model of multiple sclerosis.

Authors:  Farideh Talebi; Samira Ghorbani; Wing Fuk Chan; Roobina Boghozian; Farimah Masoumi; Sedigheh Ghasemi; Mohammed Vojgani; Christopher Power; Farshid Noorbakhsh
Journal:  J Neuroinflammation       Date:  2017-03-16       Impact factor: 8.322

10.  The neuroprotective functions of transforming growth factor beta proteins.

Authors:  Arpád Dobolyi; Csilla Vincze; Gabriella Pál; Gábor Lovas
Journal:  Int J Mol Sci       Date:  2012-07-03       Impact factor: 6.208

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.